Blog

Overview Strong clinical evidence for a dry AMD treatment device can come from a published, peer-reviewed randomized controlled trial with a sham comparator, pre-specified primary endpoints, and validated outcome measures. This design is important because it separates the effect of the active device from the non-specific improvements that result from clinical attention and expectation of…

Overview Canadian ophthalmology clinics evaluating device-based therapy for dry AMD should assess the same core dimensions as any other medical device adoption decision: Regulatory licensing, published evidence quality, patient eligibility criteria, treatment protocol, and post-market safety data. In Canada, the regulatory threshold is a Health Canada Medical Device Licence for the specific indication of dry…

Overview Optometry clinics evaluating a device-based therapy for dry AMD can assess 6 dimensions: Regulatory approval status, the quality of published clinical evidence, patient eligibility criteria and how well they match the clinic's AMD population, the defined treatment protocol, the post-market safety record and how the therapy integrates with the practice's existing monitoring and co-management…

Overview Dry AMD device providers in Australia, such as MacuMira, are optometry and ophthalmology practices that have adopted an authorized device to improve visual function and integrated it into their AMD management services. Not every eye care clinic offers MacuMira. Patients can locate providers through a device manufacturer clinic finder, by asking their current optometrist…

Overview Optometrists and ophthalmologists in Canada offer microcurrent stimulation for macular degeneration if they have adopted an authorized device and integrated it into their AMD management practice. Not every eye care clinic offers this therapy. It is available at practices that have specifically chosen to invest in the device, train their clinical team, and establish…

Overview In Canada, optometrists, ophthalmologists, and retinal specialists can manage dry AMD, depending on disease stage and the type of management offered. Optometrists are typically the first point of contact for patients and provide monitoring, lifestyle guidance, and co-management with specialists. Ophthalmologists and retinal specialists often assess more complex or advanced cases.1 The important caveat…

Overview If your macular degeneration is getting worse, the first step depends on how quickly it has changed. A sudden or rapid change in central vision, new distortion, a dark spot appearing, or a noticeable drop in vision over days rather than months warrants prompt contact with your eye care provider, as this can indicate…

Summary  Dry AMD cannot be cured, but it can be managed, and in eligible patients, visual function can be improved. Where once monitoring and nutritional supplementation were the standard method of management, MacuMira is an authorized device-based therapy available in Canada to help improve visual acuity and contrast sensitivity in appropriate patients.1 A conversation with…

Overview Dry AMD treatment devices vary significantly, from the strength and design of their supporting evidence to their regulatory approval status and scope. Clinicians evaluating devices should assess a few factors independently rather than relying on marketing materials or word of mouth. For patients, understanding these dimensions can help set realistic expectations and ask better…

Overview In Canada, Health Canada has authorized MacuMira to deliver microcurrent electrical stimulation to tissues near the eye, and it is intended to improve visual function in eligible AMD patients. The specific device a clinic uses matters because regulatory approval, published clinical evidence, and the clinician's familiarity with the device protocol all affect the quality…